Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving Average – Time to Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)’s stock price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $3.03 and traded as high as $3.60. Oramed Pharmaceuticals shares last traded at $3.59, with a volume of 436,246 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Oramed Pharmaceuticals to a “hold” rating in a research report on Saturday, November 1st. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, Oramed Pharmaceuticals currently has a consensus rating of “Hold”.

Oramed Pharmaceuticals Stock Up 5.9%

The business has a fifty day moving average of $3.03 and a 200 day moving average of $2.54. The company has a market cap of $142.88 million, a P/E ratio of 2.85 and a beta of 1.19.

Oramed Pharmaceuticals Announces Dividend

The business also recently announced a dividend, which was paid on Monday, January 26th. Stockholders of record on Friday, January 16th were given a $0.25 dividend. The ex-dividend date of this dividend was Friday, January 16th. Oramed Pharmaceuticals’s dividend payout ratio (DPR) is currently 19.84%.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ORMP. Wealth Enhancement Advisory Services LLC lifted its holdings in Oramed Pharmaceuticals by 36.2% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company’s stock worth $41,000 after buying an additional 5,000 shares during the period. Jane Street Group LLC raised its position in shares of Oramed Pharmaceuticals by 35.3% in the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 17,510 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Oramed Pharmaceuticals by 4.4% in the 3rd quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 6,261 shares during the period. Finally, BML Capital Management LLC boosted its position in shares of Oramed Pharmaceuticals by 2.1% during the second quarter. BML Capital Management LLC now owns 3,083,253 shares of the biotechnology company’s stock valued at $6,937,000 after purchasing an additional 62,505 shares in the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.